Photopatch testing: a consensus methodology for Europe by D.P. Bruynzeel et al.
 © 2004 European Academy of Dermatology and Venereology
 
679
 
OR IG INAL AR T I CLE
 
JEADV
 
 (2004) 
 
18
 
, 679–682
DOI: 10.1111/j.1468-3083.2004.01053.x
 
Blackwell Publishing, Ltd.
Photopatch testing: a consensus methodology for Europe
 
The European Taskforce for Photopatch Testing: †Members of the panel: D.P. Bruynzeel, the Netherlands; J. Ferguson, Scotland, UK; 
K. Andersen, Denmark; M. Gonçalo, Portugal; John English, UK; A. Goossens, Belgium; E. Holzle, Germany; S.H. Ibbotson, Scotland, UK; 
M. Lecha, Spain; P. Lehmann, Germany; F. Leonard, France; Harry Moseley, Scotland, UK; P. Pigatto, Italy; A. Tanew, Austria
 
Photobiology Unit, Ninewells Hospital, Medical School, Dundee DD19SY, UK. 
 
*
 
Corresponding author, Photobiology Unit, Ninewells Hospital, Medical 
School, Dundee DD19SY, UK, tel. +044 01382632240; fax +044 01382646047; E-mail: j.ferguson@dundee.ac.uk 
 
ABSTRACT
 
A group of interested European Contact Dermatologists/Photobiologists met to produce a consensus
statement on methodology, test materials and interpretation of photopatch testing. While it is recognized
that a range of local variables operate throughout Europe, the underlying purpose of the work is to act as an
essential preamble to a Pan European Photopatch Test Study focusing particularly on sunscreen chemicals.
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In May 2002, a panel† representing Contact Dermatology/
Photobiology/Photophysics, with a special interest in photopatch
testing (PPT) (on behalf of the European Society of Contact
Dermatitis and European Photodermatology Society), met
in Amsterdam. They came together to discuss and, if feasible,
establish a consensus methodology, a list of recommended test
agents, and interpretation guidelines for photopatch testing.
It is believed that PPT, which is the clinical investigation of
choice for suspected photocontact dermatitis/photoallergy, is
significantly underused in Europe and probably world-wide.
This is due to a number of reasons, not least of which is the
fact that responsibility for PPT has fallen between two areas of
dermatology subspecialization, the ‘photodermatologists’ who
have light-related, but lack contact experience, and vice versa
for ‘contact dermatologists’. This in part may explain the lack of
standardization throughout Europe, although there have been
local attempts at uniformity in the past.
 
1–7
 
 Despite these, even
the most recent literature shows significant differences in
methodology,
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 the agents used, test concentration and the
interpretation of results, which illustrates a level of uncertainty has
discouraged general dermatologists from using the technique.
At the meeting it was recognized that the variation in tech-
nique also related to a lack of published comparative data and
also that a degree of compromise would be required in contentious
areas and that an agreed methodology would need to be flexible
to take into account local service constraints and geographical
photoallergen exposure patterns.
 
Who should be tested?
 
It was agreed that the primary indication should be dermatitis
predominantly affecting exposed sites with or without a history
of a sunscreen reaction and that PPT should also be considered in
patients with chronic actinic dermatitis and any individual with a
photosensitive eruption for which there is no obvious diagnosis.
As with patch testing, this investigation should not be undertaken
when the skin test area is active. To avoid the effects of the angry
back syndrome it is recommended that testing be conducted on
skin that has been clinically normal for the previous 2 weeks.
Patients need to be informed of the possible risk of sensitiza-
tion as recognized in routine patch testing. It is also important
that they be aware of the possibility of strong provocation test
results as outlined in a patient information sheet. Most centres
do not yet routinely seek written consent for the procedure.
 
What type of units currently conduct 
photopatch testing?
 
From a survey that took place in 2001 (P. Lehmann, personal
communication, 2002) of 49 known PPT centres in Europe, 34
replied. From the 34 centres, 21 had separate photoirradiation
and contact allergy services. In those centres, patch tests were
applied in the allergy unit and the irradiation conducted in the
photo unit. The readings were performed by photo unit staff in
14. In 13 centres, the allergy and photo units were combined with
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all readings performed by the allergy unit. The test was performed
relatively infrequently with only two of the centres conducting
> 50 PPT/year with a mean number of tests across the group of 16.
It appears that few office dermatologists conduct PPT, an overall
picture that suggests PPT is an underused investigation within
Europe. It currently appears that PPT is best reserved for major
investigation centres either in contact or photodermatology units.
 
What agents should be tested?
 
The list of PPT agents used varies greatly between centres. Some
traditional agents now felt to be of only historical interest
included antibacterial salicylanilides, sulphonamides and the
major tranquillizers. There was agreement that these should
now be omitted from routine PPT. Over the past decade, PPT
has focused on organic sunscreens to include testing with each
patient’s own suspected products.
 
11–13
 
 In parts of Continental
Europe where topical non-steroidal anti-inflammatory agents
are routinely used and are associated with photosensitivity,
these and other less commonly reported agents should be
considered.
 
12
 
 Most photopatch test agents are available through
Hermal or Chemotechnique (Table 1).
 
Methodology
 
It was agreed that mid upper back skin, avoiding 3–5 cm on
either side of the vertebrae (the paravertebral groove area) is
the best choice of site for application of PPT agents. It was
suggested, for reasons of limited back space, that a maximum
of 30 agents be applied using the Finn Chamber technique
(Table 2). It was recommended that duplicate sets be in position
for either 24 or 48 h, after which both are removed. At this
point, one set should be covered with a ultraviolet (UV) opaque
material and the other irradiated with a calibrated metered
broad-spectrum UVA source. The type of lamp used for testing
should be noted as this may affect results.
 
14
 
 Psoralen plus UVA
fluorescent lamps are preferred
 
4
 
 because of their widespread
availability, reproducible spectrum and beam uniformity, even
though they do contain a small percentage of UVB. Although
metal halide lamps may be used, they have differences in spectra
emission depending on the type used and also have poor
beam uniformity and thus are less suitable. Although UVA
is recommended, it was recognized that our knowledge of
photoallergen wavelength dependency is incomplete. Mercury
vapour, monochromator and solar simulator sources are not
recommended for routine PPT.
 
Choice of ultraviolet dose
 
The published UVA dose has varied. It requires to be sufficient
to trigger the photoallergy response, yet not at such a level to
produce a false-positive or phototoxic response. Although we
cannot generalize for all patients and all test agents, work
conducted with promethazine suggests 5 J/cm
 
2
 
 is preferable to
10 J/cm
 
2
 
. In the absence of the required data, it was felt
reasonable to recommend 5 J/cm
 
2
 
 for routine PPT.
 
3,15–18
 
Timing of readings?
 
Readings should be recorded using the International Contact
Dermatitis Research Group (ICDRG) scoring system (Table 2),
pre-irradiation, immediately postirradiation and 48 h postir-
radiation. Further readings at 72 and 96 h postirradiation are
desirable to enable detection of crescendo or decrescendo scoring
Table 1 Photopatch test agents (applied in duplicate, one set irradiated)
Chemical Abstract 
Service (CAS) no.
Sunscreen agents* Temp. [International Nomenclature of Cosmetic Ingredients (INCI)]
Petrolatum (control) 800274-2
Octyl Methoxycinnamate(2-Ethylhexyl-p-methoxycinnamate, Parsol MCX, Eusolex 2292) 10% 5466-77-3
Benzophenone-3 (2-Hydroxy-4-methoxy benzophenone, Oxybenzone, Eusolex 4360) 10% 131-57-7
Octyl Dimethyl PABA (2-Ethylhexyl-p-dimethyl-aminobenzoate, Escalol 507, Eusolex 6007) 10% 21245-02-3
PABA (4 Aminobenzoic Acid) 10% 150-13-0
Butyl Methoxydibenzoylmethane (Parsol 1789, Eusolex 9020) 10% 70356-09-1
4-Methylbenzylidene Camphor (Eusolex 6300, Mexoryl SD) 10% 36861-47-9
Benzophenone-4 (2-Hydroxy-4-methoxy-benzophenone-5-sulphonic acid, Uvenyl MS-40) 10% 4065-45-6
Isoamyl p-methoxycinnamate (Neoheliopan, E1000) 10% 71617-10-2
Phenylbenzimidazole Sulphonic Acid (2-Phenyl-5-benzimidazolsulphonic acid, Eusolex 232) 10% 27503-81-7
Non-steroidal anti-inflammatory agents (require to be prepared ‘inhouse’)
Naproxen 5%
Ibuprofen 5%
Diclofenac 1%
Ketoprofen 2.5%
NB: All agents in petrolatum. *Available through Hermal (Trolab Patch Test Allergens) D-21462 Reinbek, Germany or Chemotechnique Diagnostics P.P. Box 80 
S320 Malmo, Sweden.
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patterns suggesting allergic and non-allergic mechanisms,
respectively.
 
5,19
 
 The panel recognized that false-positive photo-
patch tests can be produced as a result of weak irritant/allergic
responses combined with a subclinical UVA effect. It was agreed
that a positive reaction to a photoallergen and light in the
presence of negative ‘contact’ and ‘irradiation’ controls strongly
supported a photoallergic mechanism, particularly where a
strengthening response over the reading time points was recorded.
At the same time, it was felt important to recognize that
non-irradiated, test site results due to irritancy/allergy or
photoaggravation (at the irradiated site) of an irritant/allergic
reaction, phototoxicity and awareness of the possibility of
technical error, should all be identified and recorded.
 
Relevance of readings
 
In addition, it was felt important to record the relevance of the
result using a system such as COADEX. This classifies clinical
relevance of positive allergic patch test reactions as:
• current relevance (the patient has been exposed to allergen
during current episode of dermatitis and improves when the
exposure ceases);
• old or past relevance (past episode of dermatitis from exposure
to allergen);
• actively sensitized [patient presents with a sensitization (late)
reaction];
• relevance not known (not sure if exposure is current or old);
• cross-reaction (the positive test is due to cross-reaction with
another allergen);
• exposed (a history of exposure but not resulting in dermatitis
from that exposure or no history of exposure but a definite
positive allergic patch test).
(C = current; O = old; A actively sensitized; D = do not know;
EX = exposed).
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Testing the ultraviolet A photosensitive or 
immunosuppressed patient
 
When PPT a patient who has an abnormal UVA sensitivity, it is
advisable to establish the UVA minimal erythema dose (MED)
prior to PPT. Although there is a lack of recommended dose
series data, it is important to test up to and including 5 J/cm
 
2
 
with the same UVA source as used for PPT. If the MED detected
at 24 h is less than the lowest dose, it is advisable to use 50% of
this value with an awareness of the increased possibility of
photoaggravated irritant and contact reactions.
Although concomitant systemic or topical immunosuppression/
antihistaminic action may result in a false-negative result, a
positive response will be valid. In the absence of published data
on the duration/degree of immunosuppressive effect, the panel
recommends, when clinically feasible, that such therapy be
stopped for at least 2 weeks prior to PPT investigation.
 
Conclusions
 
The current differences in PPT methodology that exist within
Europe, not only send a confusing message to would-be users of
this technique, but also make it difficult to compare published
data between studies. Individual photoallergy patients and
industry need to know which agents are responsible. The safer
design of future products requires such information to be
accurate.
With this background, the panel has made a number of
simple suggestions to standardize the technique throughout
Europe. As further information becomes available, new test
agents and alterations in methodology will be appropriate. It
is felt that a European Photopatch Test Study using such a
methodology is desirable.
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